Cargando…
Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“
The key priority in patients with chronic lung diseases is currently immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); all vaccines approved for this showed high effectiveness against severe infections. For patients with chronic pulmonary diseases the recommendations...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274260/ https://www.ncbi.nlm.nih.gov/pubmed/34276271 http://dx.doi.org/10.1007/s10405-021-00402-4 |
_version_ | 1783721526707617792 |
---|---|
author | Dodt, Carolin Pletz, Mathias W. Kolditz, Martin |
author_facet | Dodt, Carolin Pletz, Mathias W. Kolditz, Martin |
author_sort | Dodt, Carolin |
collection | PubMed |
description | The key priority in patients with chronic lung diseases is currently immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); all vaccines approved for this showed high effectiveness against severe infections. For patients with chronic pulmonary diseases the recommendations by the Standing Committee on Vaccination include not only the standard vaccinations in adulthood but also the so-called indication vaccinations. These include vaccinations against pneumococci and influenza. Advances include the recent development of new pneumococcal conjugate vaccines containing additional serotypes and the recommendation of a more effective high-dose vaccine against influenza for persons over 60 years old. With the next scheduled booster vaccination against tetanus and diphtheria a combination vaccine with pertussis antigen should be used. For patients with chronic lung disease the herpes zoster vaccine is recommended over the age of 50 years. |
format | Online Article Text |
id | pubmed-8274260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-82742602021-07-12 Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“ Dodt, Carolin Pletz, Mathias W. Kolditz, Martin Pneumologe (Berl) CME The key priority in patients with chronic lung diseases is currently immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); all vaccines approved for this showed high effectiveness against severe infections. For patients with chronic pulmonary diseases the recommendations by the Standing Committee on Vaccination include not only the standard vaccinations in adulthood but also the so-called indication vaccinations. These include vaccinations against pneumococci and influenza. Advances include the recent development of new pneumococcal conjugate vaccines containing additional serotypes and the recommendation of a more effective high-dose vaccine against influenza for persons over 60 years old. With the next scheduled booster vaccination against tetanus and diphtheria a combination vaccine with pertussis antigen should be used. For patients with chronic lung disease the herpes zoster vaccine is recommended over the age of 50 years. Springer Medizin 2021-07-12 2021 /pmc/articles/PMC8274260/ /pubmed/34276271 http://dx.doi.org/10.1007/s10405-021-00402-4 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | CME Dodt, Carolin Pletz, Mathias W. Kolditz, Martin Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“ |
title | Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“ |
title_full | Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“ |
title_fullStr | Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“ |
title_full_unstemmed | Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“ |
title_short | Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“ |
title_sort | prävention durch impfung pneumologisch vorerkrankter erwachsener: pneumokokkenpneumonie, influenza, pertussis, herpes zoster und „coronavirus disease 2019“ |
topic | CME |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274260/ https://www.ncbi.nlm.nih.gov/pubmed/34276271 http://dx.doi.org/10.1007/s10405-021-00402-4 |
work_keys_str_mv | AT dodtcarolin praventiondurchimpfungpneumologischvorerkranktererwachsenerpneumokokkenpneumonieinfluenzapertussisherpeszosterundcoronavirusdisease2019 AT pletzmathiasw praventiondurchimpfungpneumologischvorerkranktererwachsenerpneumokokkenpneumonieinfluenzapertussisherpeszosterundcoronavirusdisease2019 AT kolditzmartin praventiondurchimpfungpneumologischvorerkranktererwachsenerpneumokokkenpneumonieinfluenzapertussisherpeszosterundcoronavirusdisease2019 |